A phase II trial with rosiglitazone for 6 months reported improvements in memory in AD patients who did not possess the e4 allele of the ApoE gene, but a later phase III trial using the same drug failed to confirm a protective effect [30]. The gene discussed is APOE; the disease is Alzheimer disease.